Damora Therapeutics Reports FY25 Financial Results and Recent Corporate Highlights

Damora Therapeutics reported FY25 financial results, with $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001. The company anticipates submitting an IND or CTA for DMR-001 in mid-2026 and delivering clinical proof-of-concept datasets next year. DMR-002 and DMR-003 IND or CTA submissions are expected in H2 2026 and 2027, respectively.